The drugs patents protect Methylin from generic competition. With a total of 1 patent, Methylin generic is possible to be available after the expiration of the last patent on October 7, 2024. The availability of Methylin generic version after this date may be due to a Paragraph IV challenge, which allows generic manufacturer to challenge a patent's validity.
Methylin, containing methylphenidate hydrochloride, is typically used to treat disorders like attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It aids in increasing attention and decreasing impulsiveness and hyperactivity by changing the amounts of certain natural substances in the brain.
There is 1 registered patent for Methylin, out of which none are expired. The last patent, US7691880, titled 'Methylphenidate solution and associated methods of administration and production', expires on October 7, 2024. Keep reading for more details on Methylin generic release date and patents. Below are the details of the patent: